Diffusion of precise recommendations, addressing each of the elements with the use of LAI antipsychotics, will improve clinicians’ perceived competence. It is going to also assistance to raise the percentage of patients to whom LAI Uridine 5′-monophosphate disodium salt Epigenetic Reader Domain antipsychotics will be supplied by psychiatrists as a therapeutic solution. The objective of these guidelines would be to propose a prescription framework to clinicians for the use of a distinct formulation of antipsychotics (LAI) in diverse therapeutic indications and specific clinical circumstances. The aim would be to permit clinicians to give one of the most suitable pharmaceutical methods for the individuals and to facilitate the use of LAI antipsychotics in clinical practice. The suggestions presented here from a consensus-based guidelines methodology (Formal Consensus Guidelines) arebased on scientific data and the consensus of a panel of specialists.MethodsQuestionnaire developmentInitially, we performed an evaluation in addition to a literature critique regarding the indications plus the use of LAI antipsychotics. A literature search working with the keywords “antipsychotic”, “neuroleptic”, “first-generation antipsychotic”, “atypical antipsychotic”, “second-generation antipsychotic”, “long-acting injectable”, “depot”, “depot neuroleptic” was performed in PubMed and EMBASE to find all the relevant studies published. Further references have been identified from http:www.fda.gov and http: www.ema.europa.eu. Information from all of these sources was discussed and an overview of the current proof has been graded and summarized using the French National Authority for Health (HAS) “levels of evidence” criteria [16]. Following this very first step, the scientific committee (PML, LS, MA, Pc, SG, SL) created a questionnaire consisting of 32 concerns that covered 539 therapeutic selections. The 32 inquiries were regrouped into 3 places PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/21310042 that were judged as vital: Target-population: Description from the unique indications of the LAI antipsychotics and on the most appropriate period from the illness to introduce the treatment. Prescription and use: Option of the molecule, approaches of introduction, particular techniques based on the psychiatric disorder or comorbidities, and therapy monitoring. Distinct population: Use of LAI antipsychotics in pregnant women, elderly individuals, subjects inside a precarious circumstance, and subjects possessing to be treated in a prison establishment. This questionnaire was created to become completed by an experts’ panel. The time needed for its administration was estimated at around three hours. In the time of improvement, all of the LAI antipsychotics accessible in France were proposed as therapeutic choices (Table 1). They were regrouped into 2 categories: Long-acting injectable first-generation antipsychotics (LAI FGA). Long-acting injectable second-generation antipsychotics (LAI SGA). This artificial separation FGASGA is not consensual because of their heterogeneous profiles of efficacyLlorca et al. BMC Psychiatry 2013, 13:340 http:www.biomedcentral.com1471-244X13Page three ofTable 1 LAI antipsychotics available in France (when the survey was completed)LAI second-generation antipsychotics LAI first-generation antipsychotics Risperidone microsphere Olanzapine pamoate Haloperidol decanoate Zuclopenthixol decanoate Flupentixol decanoate Fluphenazine decanoate Pipotiazine palmitateNote: as paliperidone palmitate had a marketing authorization date right after the development of these guidelines, it couldn’t be taken into account.Expert selectionThe Scientific Committee (Appendix 1) sel.